128 related articles for article (PubMed ID: 1877386)
1. Thymidylate synthase inhibitors: the in vitro activity of a series of heterocyclic benzoyl ring modified 2-desamino-2-methyl-N10-substituted-5,8-dideazafolates.
Jackman AL; Marsham PR; Moran RG; Kimbell R; O'Connor BM; Hughes LR; Calvert AH
Adv Enzyme Regul; 1991; 31():13-27. PubMed ID: 1877386
[TBL] [Abstract][Full Text] [Related]
2. ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study.
Jackman AL; Taylor GA; Gibson W; Kimbell R; Brown M; Calvert AH; Judson IR; Hughes LR
Cancer Res; 1991 Oct; 51(20):5579-86. PubMed ID: 1913676
[TBL] [Abstract][Full Text] [Related]
3. The role of the reduced-folate carrier and metabolism to intracellular polyglutamates for the activity of ICI D1694.
Jackman AL; Gibson W; Brown M; Kimbell R; Boyle FT
Adv Exp Med Biol; 1993; 339():265-76. PubMed ID: 7513935
[TBL] [Abstract][Full Text] [Related]
4. The biochemical pharmacology of the thymidylate synthase inhibitor, 2-desamino-2-methyl-N10-propargyl-5,8-dideazafolic acid (ICI 198583).
Jackman AL; Newell DR; Gibson W; Jodrell DI; Taylor GA; Bishop JA; Hughes LR; Calvert AH
Biochem Pharmacol; 1991 Oct; 42(10):1885-95. PubMed ID: 1741766
[TBL] [Abstract][Full Text] [Related]
5. Biochemical effects of folate-based inhibitors of thymidylate synthase in MGH-U1 cells.
Mitrovski B; Pressacco J; Mandelbaum S; Erlichman C
Cancer Chemother Pharmacol; 1994; 35(2):109-14. PubMed ID: 7987985
[TBL] [Abstract][Full Text] [Related]
6. Activity of the thymidylate synthase inhibitor 2-desamino-N10-propargyl-5,8-dideazafolic acid and related compounds in murine (L1210) and human (W1L2) systems in vitro and in L1210 in vivo.
Jackman AL; Taylor GA; O'Connor BM; Bishop JA; Moran RG; Calvert AH
Cancer Res; 1990 Sep; 50(17):5212-8. PubMed ID: 2386929
[TBL] [Abstract][Full Text] [Related]
7. Thymidylate synthase: a target for anticancer drug design.
Harrap KR; Jackman AL; Newell DR; Taylor GA; Hughes LR; Calvert AH
Adv Enzyme Regul; 1989; 29():161-79. PubMed ID: 2633608
[TBL] [Abstract][Full Text] [Related]
8. Multiple membrane transport systems for the uptake of folate-based thymidylate synthase inhibitors.
Jansen G; Schornagel JH; Westerhof GR; Rijksen G; Newell DR; Jackman AL
Cancer Res; 1990 Dec; 50(23):7544-8. PubMed ID: 2253202
[TBL] [Abstract][Full Text] [Related]
9. Folate-based inhibitors of thymidylate synthase: synthesis and antitumor activity of gamma-linked sterically hindered dipeptide analogues of 2-desamino-2-methyl-N10-propargyl-5,8-dideazafolic acid (ICI 198583).
Bavetsias V; Jackman AL; Marriott JH; Kimbell R; Gibson W; Boyle FT; Bisset GM
J Med Chem; 1997 May; 40(10):1495-510. PubMed ID: 9154971
[TBL] [Abstract][Full Text] [Related]
10. The measurement of polyglutamate metabolites of the thymidylate synthase inhibitor, ICI D1694, in mouse and human cultured cells.
Gibson W; Bisset GM; Marsham PR; Kelland LR; Judson IR; Jackman AL
Biochem Pharmacol; 1993 Feb; 45(4):863-9. PubMed ID: 7680860
[TBL] [Abstract][Full Text] [Related]
11. In vitro uptake, anabolism, and cellular retention of 1843U89 and other benzoquinazoline inhibitors of thymidylate synthase.
Hanlon MH; Ferone R
Cancer Res; 1996 Jul; 56(14):3301-6. PubMed ID: 8764125
[TBL] [Abstract][Full Text] [Related]
12. ICI D1694, an inhibitor of thymidylate synthase for clinical study.
Jackman AL; Jodrell DI; Gibson W; Stephens TC
Adv Exp Med Biol; 1991; 309A():19-23. PubMed ID: 1789205
[TBL] [Abstract][Full Text] [Related]
13. Carrier- and receptor-mediated transport of folate antagonists targeting folate-dependent enzymes: correlates of molecular-structure and biological activity.
Westerhof GR; Schornagel JH; Kathmann I; Jackman AL; Rosowsky A; Forsch RA; Hynes JB; Boyle FT; Peters GJ; Pinedo HM
Mol Pharmacol; 1995 Sep; 48(3):459-71. PubMed ID: 7565626
[TBL] [Abstract][Full Text] [Related]
14. Folate-based thymidylate synthase inhibitors as anticancer drugs.
Jackman AL; Calvert AH
Ann Oncol; 1995 Nov; 6(9):871-81. PubMed ID: 8624289
[TBL] [Abstract][Full Text] [Related]
15. Formation and retention and biological activity of N10-propargyl-5,8-dideazafolic acid (CB3717) polyglutamates in L1210 cells in vitro.
Sikora E; Jackman AL; Newell DR; Calvert AH
Biochem Pharmacol; 1988 Nov; 37(21):4047-54. PubMed ID: 2461200
[TBL] [Abstract][Full Text] [Related]
16. Kinetic characteristics of ICI D1694: a quinazoline antifolate which inhibits thymidylate synthase.
Ward WH; Kimbell R; Jackman AL
Biochem Pharmacol; 1992 May; 43(9):2029-31. PubMed ID: 1596289
[TBL] [Abstract][Full Text] [Related]
17. The renal effects of N10-propargyl-5,8-dideazafolic acid (CB3717) and a non-nephrotoxic analogue ICI D1694, in mice.
Jodrell DI; Newell DR; Morgan SE; Clinton S; Bensted JP; Hughes LR; Calvert AH
Br J Cancer; 1991 Nov; 64(5):833-8. PubMed ID: 1931603
[TBL] [Abstract][Full Text] [Related]
18. Quinazoline thymidylate synthase inhibitors: methods for assessing the contribution of polyglutamation to their in vitro activity.
Jackman AL; Kimbell R; Brown M; Brunton L; Boyle FT
Anticancer Drug Des; 1995 Oct; 10(7):555-72. PubMed ID: 7495479
[TBL] [Abstract][Full Text] [Related]
19. Increased thymidylate synthase in L1210 cells possessing acquired resistance to N10-propargyl-5,8-dideazafolic acid (CB3717): development, characterization, and cross-resistance studies.
Jackman AL; Alison DL; Calvert AH; Harrap KR
Cancer Res; 1986 Jun; 46(6):2810-5. PubMed ID: 2938731
[TBL] [Abstract][Full Text] [Related]
20. Quinazoline-based thymidylate synthase inhibitors: relationship between structural modifications and polyglutamation.
Jackman AL; Kimbell R; Brown M; Brunton L; Bisset GM; Bavetsias V; Marsham P; Hughes LR; Boyle FT
Anticancer Drug Des; 1995 Oct; 10(7):573-89. PubMed ID: 7495480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
